Voloridge Investment Management LLC Takes Position in argenx SE (NASDAQ:ARGX)

Voloridge Investment Management LLC bought a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 46,357 shares of the company's stock, valued at approximately $28,510,000. Voloridge Investment Management LLC owned about 0.08% of argenx at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ARGX. Point72 Europe London LLP acquired a new stake in shares of argenx in the 4th quarter valued at approximately $5,839,000. Stephens Inc. AR bought a new stake in argenx in the fourth quarter valued at approximately $310,000. Jones Financial Companies Lllp raised its holdings in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares during the period. Atomi Financial Group Inc. acquired a new stake in argenx in the fourth quarter worth $339,000. Finally, Wilmington Savings Fund Society FSB boosted its position in shares of argenx by 47.8% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 1,776 shares of the company's stock worth $1,092,000 after purchasing an additional 574 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on ARGX shares. Oppenheimer upped their price objective on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. JMP Securities set a $699.00 target price on argenx in a research note on Wednesday, May 14th. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Citigroup reiterated a "buy" rating on shares of argenx in a report on Wednesday, May 21st. Finally, Robert W. Baird raised argenx from a "neutral" rating to an "outperform" rating and set a $680.00 target price for the company in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, twenty have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, argenx presently has an average rating of "Buy" and an average target price of $698.11.

argenx Price Performance

NASDAQ:ARGX traded down $3.35 on Tuesday, hitting $584.26. 122,795 shares of the company's stock were exchanged, compared to its average volume of 324,701. The firm has a 50-day moving average price of $589.13 and a 200-day moving average price of $613.08. argenx SE has a 52 week low of $359.37 and a 52 week high of $678.21. The company has a market cap of $35.67 billion, a P/E ratio of -662.64 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. On average, research analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.